GeNeuro SA
GNRO
Company Profile
Business description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Contact
3 chemin du Pre-Fleur
Plan-les-Ouates
Geneva1228
CHET: +41 225524800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,631.50 | 42.70 | 0.50% |
| CAC 40 | 7,826.79 | 1.34 | -0.02% |
| DAX 40 | 24,226.49 | 198.84 | 0.83% |
| Dow JONES (US) | 42,308.91 | 705.84 | 1.70% |
| FTSE 100 | 8,778.05 | 60.08 | 0.69% |
| HKSE | 23,381.99 | 99.66 | 0.43% |
| NASDAQ | 19,196.62 | 459.41 | 2.45% |
| Nikkei 225 | 37,724.11 | 192.58 | 0.51% |
| NZX 50 Index | 12,582.33 | 35.11 | 0.28% |
| S&P 500 | 5,919.81 | 116.99 | 2.02% |
| S&P/ASX 200 | 8,407.60 | 46.60 | 0.56% |
| SSE Composite Index | 3,340.69 | 6.15 | -0.18% |